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vectors aremeasured by quantifying viral genomes. It is generally
perceived that AAV virions disassemble and release DNA upon
thermal treatment. Here, we present data on enzymatic accessi-
bility of rAAV genomes when AAV virions were subjected to
thermal treatment. For rAAV vectors with a normal genome
size (%4.7 kb), thermal treatment at 75C–99C allowed only
10% of genomes to be detectable by quantitative real-time
PCR. In contrast, greater than 70% of AAV genomes can be de-
tected under similar conditions for AAV vectors with an over-
sized genome (R5.0 kb). The permeability of virions, as
measured by ethidium bromide (EB) staining, was enhanced by
thermal stimulation. These results suggest that in rAAV virions
with standard-sized genomes, the capsid and DNA are close
enough in proximity for heat-induced “crosslinking,” which re-
sults in inaccessibility of vector DNA to enzymatic reactions. In
contrast, rAAV vectors with oversized genomes release their
DNA readily upon thermal treatment. These findings suggested
that the spatial arrangement of capsid protein and DNA in
AAV virions is genome-size dependent. These results provide a
foundation for future improvement of vector assays, design,
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Adeno-associatedvirus (AAV) is a single-strandedDNA(ssDNA),non-
enveloped virus of the Parvoviridae family andDependovirus genus. It is
characterized as a 20- to 25-nm particle, carrying a genome of 4.7 kb in
length.Recombinant vectorsderived fromAAV(rAAV)are apromising
tool for delivering nucleic acid content into target tissues, showing
notable potential for endpoint applications in clinical therapy for pa-
tients with genetic diseases. AAV vectors designed to carry a genome
larger than the standard 4.7 kb have been tested for use in gene delivery,
despite their limited vector yield and nonhomogeneous viral genomes.1–
3
The DNA genome in an AAV virion is surrounded by a capsid
comprised of sixty proteins, including the VP1, VP2, andVP3 proteins,328 Molecular Therapy: Methods & Clinical Development Vol. 18 Septe
This is an open access article under the CC BY-NC-ND license (httpassembled in an approximate ratio of 1:1:10;4 the exact distribution de-
pends on the serotype.5 AAV capsids are critical components to deliv-
ering genes in vivo. On the cellular level, capsids are involved in cell
binding, internalization, and trafficking processes within host cells.6–8
At the systemic level, AAVcapsids play a key role in the delivery process
by dictating tissue tropism,9,10 immunogenicity,11,12 and transduction
efficacy in vivo.13,14 Due to their importance in vector efficacy, there
has been great effort in the field to bioengineer AAV capsids with the
ultimate goal of refining the properties of rAAV vectors to promote
more favorable interactions with the host. Researchers have addressed
this aim with emphasis on screening AAV capsid libraries to identify
new serotypes that exhibit performance at an equivalent, or higher level,
than the currently used serotypes in cell or tissue applications.15–18
Specific attention has also been directed toward understanding the
biophysical properties of AAV capsids. The thermal stability of
AAV particles has been the subject of recently published studies,
which is imperative to AAV genome stability both in vitro and
in vivo.19–22 Studies have shown that capsid stability is notably pre-
served in temperatures of 4C–55C and a pH ranging from 5.5 to
8.5.23 This stability is maintained in the face of interactions with
human or mice serum, as well as nonorganic materials, like glass,
polystyrene, polyethylene, polypropylene, and stainless steel.24 Addi-
tionally, studies employing electron microscopy (EM), atomic force
microscopy (AFM), and fluorometric assays have demonstrated
that the biophysical and ultrastructural properties of the AAV capsid
fluctuate with thermal changes in a given setting.21,25,26 Other recent
studies have indicated that AAV capsid stability may vary by serotypember 2020 ª 2020
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Evaluation of the Thermostability of AAV2-GFP Preparations
(A) Outline of experimental procedures for thermal treatment of AAV vectors, followed by genome detection via quantitative real-time PCR. (B) Assessment of the efficacy of
DNase I treatment. Plasmids pssAAV-CB-GFP and AAV production helpers were transfected to 293 cells using PolyJet and incubated for 72 h before they are harvested for
the assay. pssAAV-CB-GFP is the DNA standard. DMEM is the mock control without vector DNA. DMEM + plasmid is mock media spiked with standard DNA and treated
with DNase I. Harvested cell lysate and medium, which are transfected with only PolyJet plus standard pssAAV-CB-GFP, are treated with DNase I. Harvested cell lysate and
medium with AAV vector DNA are treated with DNase I. Harvested cell lysate and medium with AAV vector DNA are spiked with the standard pssAAV-CB-GFP and treated
with DNase I. This result showed that all plasmid DNAs are completely eradicated by DNase I digestion. (C) The number of AAV2-GFP particles per milliliter uncoated during
heating for 1060 min at 95C or 99C, as detected by quantitative real-time PCR assay. (D) Stability of thermal-treated AAV-capsid complex. AAV particles were initially
treated at 99C and then incubated with DNase I to remove released DNA. The resulting DNA-capsid complex was then heat treated again at 99C, and the released DNA
was quantitative real-time PCR quantified. The y axis shows the amount of DNA resulting from the heat-treatment time. The data are presented with as mean ± SD.
www.moleculartherapy.organd the nature (single stranded or double stranded) and length of the
vector DNA packaged inside.19,21,25 However, it has also been sug-
gested that AAV vector stability was governed by VP3 alone, primar-
ily due to its ratio of basic/acidic amino acids, and was independent of
VP1 and VP2 or the genome packaged.20 This apparent discrepancy
in the findings might originate from the variance in measurement
methods utilized, and it remains unclear how these physical measures
relate to the biological properties of the viral particles.
In the current study, we explored enzymatic accessibility of the AAV
genome upon thermal treatment utilizing quantitative real-time PCR
and ethidium bromide (EB) staining. Through this, we attempt to
gain further understanding on the relationship between the AAV
capsid and its genome, as influenced by the condition of thermal
treatment, and to provide more information on the biophysical char-
acteristics of AAV.
RESULTS
The AAV Capsid Protects the Viral Genome from Release upon
Thermal Induction
Heat denaturation of AAV vectors is a common method for releasing
AAV genomes to use in subsequent assays. In previously reportedMolecular Thestudies, AAV capsids were found to undergo ultrastructural transi-
tions and permeability changes in response to transient heat-
ing.25,27,28 The approaches used in these studies were adapted to
further explore the impact of thermal heating on AAV DNA release
from the capsid (Figure 1A). To eliminate residual plasmid contam-
inants from the preceding transfection, AAV2-CB (beta-actin pro-
moter with CMV enhancer) -GFP vectors (2.4 kb) from various sour-
ces, including crude media and cell lysate, were first treated with
DNase I extensively. The results demonstrated that DNase I treat-
ment was sufficient to remove all remnants of plasmid DNA, and
any DNA detected thereafter originated solely from the AAV vectors
(Figure 1B). The samples were then incubated at 95C or 99C over
the course of 10 to 60 min and the extent of genome release assessed
by quantitative real-time PCR assay. The results found that only a mi-
nority (10%–16%) of the total vectors, as measured through em-
ploying a lysis and proteinase K digestion step to ensure the release
of all genomes, could be detected (Figure 1C). To confirm that
heat-denatured AAV capsids prevented the DNA genomes from
detection by quantitative real-time PCR and not that the capsid had
simply prevented the release of DNA, the samples analyzed in Fig-
ure 1C were subjected to another round of DNase I treatment, and
then the remaining capsid was treated with additional heatrapy: Methods & Clinical Development Vol. 18 September 2020 329
Figure 2. Characterization of AAV2-GFP Particles
Following Thermal Treatment
(A) Agarose gel electrophoresis of AAV2-GFP particles.
AAV vectors, treated under varying temperature for
10 min, were loaded to 1% agarose gel in Tris-acetate-
EDTA (TAE) buffer and separated by electrophoresis in the
presence of ethidium bromide. Lane order, lane 1: DNA
marker; lane 2: untreated AAV; lanes 3–5: 55C-, 65C-,
and 75C-treated AAV; lane 6 (75C+ lysis buffer): 75C in
the presence of lysis buffer; lane 7 (control): AAV treated at
75C in the presence of lysis buffer and incubated with
proteinase K digestion. (B) Quantitation of observed fluo-
rescence of DNA bands representing released or un-
released genomes shown in (A). Lane 5 represents total
AAV genome. The data are presented with as mean ± SD.
Molecular Therapy: Methods & Clinical Developmentdenaturation. As presented in Figure 1D, further thermal treatment
failed to release additional significant amounts of vector genomes.
Only less than 2% of the total vectors were detected upon the second
round of heat treatment.
To confirm that the genomes remained associated with the AAV cap-
sids following heat denaturation, AAV vectors treated at varying tem-
peratures were subjected to agarose gel electrophoresis and the vector
genomes detected by EB. In this analysis, AAV genomes released
from the capsid migrated normally in the gel, and the vector DNA
associated with the capsid migrated more slowly, which resulted in
two distinct band (Figure 2A). The bands located at the point of origin
represent unreleased genomes associated with the capsid and the
permeability of the AAV capsid, whereas the downstream bands
are genomes that have been released from their capsids. Only at the
higher exposure temperature of 75C does the DNA of released ge-
nomes become visible, with 8.3% of the total genome being released
(Figures 2A and 2B). The amount of vector genomes shown at the
origin of the gel suggested that the permeability of the AAV capsid
to EB conspicuously increased from 21.7% to 91.6% along a temper-
ature gradient from 55C to 75C (Figures 2A and 2B). These results
demonstrate that AAV capsids exposed to thermal treatment have
enhanced permeability. This allows small molecules, such as EB, to
enter and bind DNA inside the capsid despite retention of overall
capsid integrity, which hinders detection via quantitative real-time
PCR.
Effects of the Capsid Serotype Show Varying Vector Genome
Release Following Heat Treatment
To determine if thermal stability was serotype dependent, rAAV,
based on serotype AAV1, -2, -5, -8, and -9, was heat treated at
75C and 95C and the vector genomes released quantified by quan-
titative real-time PCR (Figure 3). For all AAV serotypes assessed, only
a small portion of the total genomes were detected, ranging from
0.07% to 9.75% at 75C and 2.47% to 13.2% at 95C, respectively.
For AAV2, 10%–13% of the genomes were detectable by quantitative
real-time PCR assay. In contrast, very few AAV8s were detected upon
75C treatment and only 2.5% genomes detected after heat treatment
at 95C. Other serotypes showed varying results following heat treat-330 Molecular Therapy: Methods & Clinical Development Vol. 18 Septement. The results indicate that the majority of vector genomes are not
accessible for quantitative real-time PCR detection for all serotypes
tested. However, different capsids exhibited varying differences in
the amount of vector genomes that become accessible upon exposure
to heat treatment.
Vector Genome Size Affects DNA Release Following Thermal
Treatment
The packaging capacity of AAV vectors has been thoroughly charac-
terized.29–33 Numerous studies have demonstrated successful trans-
duction of cells by oversized AAV vectors.34–36 To assess the thermal
profile of AAV vectors with an oversized genome, rAAVs carrying ge-
nomes of 5.0–5.2 kb were made and analyzed. The results found that
the percentage of genomes detected out of total vectors increased with
genome length (Figure 4). For a genome size of 5.0, 68.8% of vectors
were detected after treatment at 75C and increased to 70.4% after
treatment at 95C. For a genome size of 5.1, 82.5% of vectors were de-
tected after treatment at 75C and increased to 92.7% after treatment
at 95C. For a genome size of 5.2, 87.3% of vectors were detected after
treatment at 75C and increased to 98.1% after treatment at 95C
(Figures 4A and 4B).
Next, capsid permeability of oversized vectors undergoing heat treat-
ment was assessed using an agarose gel assay (Figures 4C and 4D).
The vector DNA of AAV-5.0 kb treated at 55C–65C mostly re-
mained at the top of the gel, showing no obvious DNA release from
the virion. For AAV-5.1 kb and AAV-5.2 kb, free migrating DNA
started to become visible even after heat treatment as low as 50C.
The quantification of DNA released is shown in Figures 4D–4F. For
AAV-5.0 kb, the maximal released genome was approximately
36.2% at 75C, which was similar to the larger vectors, AAV-5.1 kb
(36% at 50C) and AAV-5.2 kb (41% at 50C). These results suggest
that compared to AAV capsids containing normal-sized genomes,
capsids carrying oversized genomes are significantly less protective.
DISCUSSION
Capsid stability has a direct association with the AAV-uncoating pro-
cess, in which AAV releases its genome once inside the host cell.37–39
In addition to ambient pH and the composition of the buffer solutionsmber 2020
Figure 3. Evaluation of the Genome Accessibility of
Various AAV Serotypes under Heat Treatment
(A) The number of AAV-GFP particles per milliliter released
after heating for 10 min at 75C or 95C, as detected by
quantitative real-time PCR assay. (B) The percentage of
AAV-GFP particles uncoated after thermal treatment. The
total possible number of genomes released was defined by
vectors treated with a lysis buffer along with proteinase K
digestion. The data are presented with as mean ± SD.
www.moleculartherapy.orgused to store AAV vectors, temperature is another important factor
affecting capsid stability.24 Studies have found that pH-dependent
protease activation sites exist on the AAV capsids, making capsid pro-
teins sensitive to pH induction, with significant autocleavage occur-
ring at pH 5.5.40,41 Although the optimal packaging capacity of
rAAV is 4.7 kb, an oversized genome can be packaged up to a limit
of 5.3 kb.28 Vector genome size also affects AAV stability.
In the current study, the primary goal was to assess the vector DNA
enzymatic accessibility followingheat treatment. Although this is related
to vector stability, it is different in that the denatured/disintegrated cap-
sidsmaynot have biological activities yet remain associatedwith the vec-
torDNA restricting enzymatic accessibility. In standard-sizedAAVpar-
ticles, exposure to thermal stress under 75C only resulted in less than
10% of total vector genomes to be detected by quantitative real-time
PCR. When the temperature was raised to 95C, the number of detect-
able genomes increased slightly to 16%. These results are consistentwith
the reported amount of linear ssDNAejected frommostly intact capsids,
as described by Bernaud et al.21 On the other hand, the accessibility of
vector DNA is not an issue since all vector genomes can be released
by the treatment of a lysis buffer along with proteinase K digestion.
This result also suggests that themajority of vector genomes are shielded
by the capsid, even after heat denaturation as high as 95C.
A fewmethods have been used to assess thermal stability, such as anti-
body binding, deferential scanning calorimetry (DSC), deferential
scanning fluorimetry (DSF), and EM. All of these methods monitored
capsid disintegration. With the use of DSF, DSC, and EM, AAV2 and
AAV8 melting temperature (Tm) was determined to be 68C and
71C.19,20,24,42,43 With the use of antibody binding and DNase/quan-
titative real-time PCR, the transition temperature of AAV2 and
AAV8 was determined to be between about 55C to 70C,44 whereas
the EM and SYBR Gold method showed a transition between 40C
and 70C.25 The combination of DNase I treatment and quantitative
real-time PCR found for several AAV derivatives a dissociation tem-
perature (Td) of 56C. With the use of AFM, more than 60% of
DNA in AAV8 was shown to be linearly ejected at 75C, and 30%
of virions were a ruptured particle.21 Although these methods
observed the perturbation of the intact capsid particle, they did not
assess vector genome enzymatic accessibility quantitatively. These
methods, in combination with the enzymatic accessibility analysis
in this study, allow us to have a better understanding of the arrange-
ment of the viral capsid and its DNA content.Molecular TheThe DNA enzymatic accessibility of oversized AAV particles (5.0–5.2
kb) upon heat denaturation was considerably better than the stan-
dard-sized AAV vector, reaching approximately 69%–87% at 75C
and 70%–98% at 95C by quantitative real-time PCR assay. These re-
sults demonstrate a correlation between genome size and the AAV
capsid following thermal treatment. As revealed by EB staining, the
permeability of the AAV capsid became further enhanced as the
magnitude of thermal stimuli increased. Horowitz et al.25 used
computational modeling of internal capsid pressure and genome or-
ganization to explain the reverse relationship between the AAV
capsid thermal stability and genome size. The accessibility of the de-
natured AAV genome is consistent with the vector thermal stability.
Themain use of heat denaturation ofAAVvectors is tomeasure vector
titer using quantitative real-time PCR. Inaccessibility of heat-treated
virion undoubtedly is the main source of systemic error, yet previous
studies did not consider this issue. For example, in a previous reported
study,44,45 heat-treated vectors are assumedly deemed 100% accessible
by quantitative real-time PCR and used as the basis for the subsequent
data analysis. Although this would not change the overall conclusion
for these particular studies, it does indicate that the total amount of
vector was underestimated. This is supported by the fact that alkaline
lysis buffer plus proteinase K digestion releasedmore vectors that were
detected by quantitative real-time PCR (Figure 2).
Based on the results of this study, we proposed a model relating the
state of the capsid proteins and its DNA content upon heat stimula-
tion, which is summarized in Figure 5. The key point is that the capsid
protein, albeit denatured, may still be associated with vector DNA.
The resulting “heat crosslinked” product is rather stable and perme-
able to the small molecules, such as DNA dye. However, they are inac-
cessible to common enzymes, such as thermostable polymerases, used
in the DNA assay. It reflects a special DNA and capsid protein
arrangement in the virion.
MATERIALS AND METHODS
Virus Production and Purification
AAV vectors were generated using the triple-plasmid cotransfection
method. Plasmids for pssAAV-CB-EGFP (2.4 kb), pssAAV-CB-GFP-
XhoI (4.3 kb), pssAAV-b-actin-hF8-5p (5.1 kb), and pssAAV-
b-actin-hF8-5p inserted with a synthesized 100-bp (5.2-kb) fragment
were packaged in AAV vectors as described previously.46,47 Briefly,
AAV helper plasmids for serotype 1, 2, 5, 8, or 9, pFD6 helper, andrapy: Methods & Clinical Development Vol. 18 September 2020 331
Figure 4. Evaluation of the Thermal Stability of Oversized Genome AAV Preparations
(A) The number of AAV8-factor VIII (FVIII) particles per milliliter released after heating for 10 min at 75C or 95C, as detected by quantitative real-time PCR assay. (B) The
percentage of AAV8-FVIII particles released during hyperthermal treatment. The total possible number of genomes released was defined by vectors treated with a lysis buffer
and proteinase k digestion. (C). Agarose gel electrophoresis of AAV particles following thermal treatment at 50C, 55C, 60C and 75C. (D). Agarose gel electrophoresis of
AAV particles following thermal treatment at 65C, 75C. The control is AAV treated with proteinase K digestion. In respective order, (C) lanes 1~6: marker, untreated, 50C,
55C, 60C, and 75C and (D) lanes 1~5: marker, untreated, 65C, 75C, and control. *Unreleased genomes; **released genomes. (E). Quantitation of observed fluo-
rescence of DNA bands representing released or unreleased genomes showing in (C). (F). Quantitation of observed fluorescence of DNA bands representing released or
unreleased genomes showing in (D). The data are presented with as mean ± SD.
Molecular Therapy: Methods & Clinical Developmentthe transgene plasmids were cotransfected into HEK293 cells at a 1:1:1
ratio and cultured in roller bottles. The vectors in transfected cells and
culturemediawere harvested 72h post-transfection andpurifiedby two
rounds of CsCl gradient ultracentrifugation and then extensively dia-
lyzed against phosphate-buffered saline (PBS; NaCl 137 mM, KCl
2.7 mM, Na2HPO4 10 mM, KH2PO4 1.8 mM, pH 7.2) containing 5%
D-sorbitol. Vector genome titers were determined by silver-stain assay
and additionally verifiedbyquantitative real-timePCRwith vector titers
expressed as vector genomes/milliliter, as described previously.48,49
Quantitative Real-Time PCR Assay for Detection of Thermally
Induced Genome Release
Viral vectors (1 1010 vector genomes, 1 mL) in DNase solution con-
taining DNase I (1 U/mL) were incubated for 30 min at 37C, adding
1 mL of 0.5 M EDTA (to a final concentration of 5 mM), and subse-
quently heated for 10 min at 75C to cease DNase I activity. Control332 Molecular Therapy: Methods & Clinical Development Vol. 18 Septesamples each received lysis buffer containing proteinase K (40 mg/
mL), then were incubated for 1 h at 56C, and finally heated for
10 min at 95C. The samples intended for thermal treatment were
directly heated following heat inactivation of DNase I treatment at
the indicated temperatures. The copy numbers of viral genomes sub-
sequently released were quantified by real-time PCR and expressed in
vector genomes/milliliter. The primers used are targeting the GFP
gene, forward 50-TGACCCTGAAGTTCATCTGC-30, reverse 50-GA
AGTCGTGCTGCTTCATGT-30; and the F8 gene, forward 50-CACC
CTGATGGTGTTCTTTG-30, reverse 50-GCCTGATGTATCTG
GCAATG-30.
Agarose Gel Assay for Visualization of Thermally Induced
Genome Release
For control group, the sample was treated according to conventional
protocol: viral vectors (1  1011 vector genomes, 10 mL) in DNasember 2020
Figure 5. A Hypothetical Model for AAV Genome
DNA under Thermal Treatment
Upon heat treatment, normal-sized AAVs mostly have a
majority of vector DNA associated with vector capsid,
which is not accessible by quantitative real-time PCR
assay. In contrast, heat treatment of the oversized AAV
vectors allows themajority of AAV genomes to be assayed
by quantitative real-time PCR assay. The denatured AAV
particles, even though they may not have biological ac-
tivity, are in a special configuration in which the DNA may
not be accessible enzymatically.
www.moleculartherapy.orgsolution containing DNase I (1 U/mL) were incubated for 30 min at
37C, adding 1 mL of 0.5 M EDTA (to a final concentration of 5 mM),
and subsequently heated for 10 min at 75C to cease DNase I activity.
Subsequently, the viral vectors were exposed to lysis buffer containing
proteinase K (40 mg/mL), then incubated for 1 h at 56C, and finally
heated for 10 min at 95C. For experiment groups, the equal amounts
of viral vectors (1 1011 vector genomes, 10 mL) were directly heated
at the indicated temperatures 50C, 55C, 60C, 65C, and 75C for
10 min. Untreated vectors were set as the negative control. The
amount of each AAV vector sample used for loading onto the agarose
gel containing EB was adjusted to a final concentration of 0.5 mg/mL
for detection of thermally induced genome release. Images were
captured with the aid of UV light, and fluorescence levels were
analyzed by GelAnalyzer 2010a software. The bands detained in the
wells are intact viral particles with genomes still inside, whereas the
bands that migrated downward through the gel represent viral ge-
nomes released from uncoated viral particles.
Data were normalized to baseline spectra obtained prior to and after
complete thermal transition to determine the ratio of uncoated parti-
cles to intact particles.
Statistical Analysis
The data are presented with as mean ± SD. Statistical analysis was
performed using Student’s unpaired t test in SPSS software. A value
of p <0.05 was considered statistically significant.
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